NCT07114640View on ClinicalTrials.gov

The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

August 7, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Urinary Bladder, Overactive
Interventions
DRUG

Mirabegron 25mg

Taking 25 mg mirabegron in the nighttime

DRUG

Solifenacin 5 mg

Taking 5 mg solifenacin in the nighttime

DRUG

Tolterodine 4 mg

Taking 5 mg tolterodine in the nighttime

DRUG

Oxybutynin ER 5 mg

Taking 5 mg oxybutynin ER in the nighttime

Trial Locations (1)

22050

Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital,, Banqiao District

All Listed Sponsors
lead

Far Eastern Memorial Hospital

OTHER